Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/267256
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment |
Autor: | López-Nieva, Pilar CSIC ORCID; González-Sánchez, Laura CSIC ORCID; Cobos-Fernández, María A.; Córdoba, Raúl; Santos, Javier CSIC ORCID; Fernández-Piqueras, José CSIC ORCID | Palabras clave: | Broad-spectrum γ-secretase inhibitors PF-03084014 treatment MYC gene dosage T-cell lymphoblastic cell lines New resistance factor Selective γ-secretase inhibitors |
Fecha de publicación: | 2021 | Editor: | AlphaMed Press | Citación: | Oncologist 26: e298- e305 (2021) | Resumen: | The NOTCH1 gene encodes a transmembrane receptor protein with activating mutations observed in many T¿cell acute lymphoblastic leukemias (T¿ALLs) and lymphomas, as well as in other tumor types, which has led to interest in inhibiting NOTCH1 signaling as a therapeutic target in cancer. Several classes of Notch inhibitors have been developed, including monoclonal antibodies against NOTCH receptors or ligands, decoys, blocking peptides, and ¿¿secretase inhibitors (GSIs). GSIs block a critical proteolytic step in NOTCH activation and are the most widely studied. Current treatments with GSIs have not successfully passed clinical trials because of side effects that limit the maximum tolerable dose. Multiple ¿¿secretase¿cleavage substrates may be involved in carcinogenesis, indicating that there may be other targets for GSIs. Resistance mechanisms may include PTEN inactivation, mutations involving FBXW7, or constitutive MYC expression conferring independence from NOTCH1 inactivation. Recent studies have suggested that selective targeting ¿¿secretase may offer an improved efficacy and toxicity profile over the effects caused by broad¿spectrum GSIs. Understanding the mechanism of GSI¿induced cell death and the ability to accurately identify patients based on the activity of the pathway will improve the response to GSI and support further investigation of such compounds for the rational design of anti¿NOTCH1 therapies for the treatment of T¿ALL. | Versión del editor: | http://dx.doi.org/10.1002/onco.13595 | URI: | http://hdl.handle.net/10261/267256 | DOI: | 10.1002/onco.13595 | Identificadores: | doi: 10.1002/onco.13595 issn: 1549-490X |
Aparece en las colecciones: | (CBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Fernández-PiquerasJ_MoreInsightsOnTheUse.pdf | 1,55 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
Page view(s)
37
checked on 16-may-2024
Download(s)
37
checked on 16-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons